Author: equipe
15 Dec Publication of the CellProthera phase I/IIb study design in the ESC Heart Failure Journal
Great news of December 15th 2024!
13 Dec CellProthera Signs MOU with Shonan Kamakura General Hospital for Use of StemXpand® in Japanese Stem Cell Clinical Trial
CellProthera will carry out technology transfer ahead of autologous CD34+ endothelial progenitor cell clinical trials planned by Dr. Takayuki Asahara and his team in 2025.
04 Oct Drug TARGET REVIEW: Cell and gene therapy development moves into cardiac indications
The success of CAR-Ts in oncology has stoked enthusiasm for developing comparable curative therapies in other disease areas. CellProthera’s Chief Scientific Officer, Ibon Garitaonandia, explains the potential and progress for CGTs in cardiology, where disease-modifying therapies are largely non-existent.
02 Sep CellProthera inches closer to Phase III trial for heart attack cell therapy
Speaking at a press conference, CellProthera’s CEO said the company is moving into the final phase of clinical development for its product.
31 Aug Euro Health Leaders: Navigating the Challenges of Autologous Cell Therapy Production
Revolutionizing Cardiac Regeneration.
30 Aug CellProthera shares U.S. regulatory progress of ProtheraCytes® cell therapy program
Positive pre-IND meeting with FDA helps position CellProthera for a U.S. and international Phase III trial for...
07 Aug CellProthera begins long-term observational study to demonstrate safety and efficacy of ProtheraCytes® cell therapy in acute myocardial infarction
The long-term PERFECT observational study follows patients from successful Phase I/IIb of ProtheraCytes for the repair and...
12 Jul CellProthera and BioCardia Collaborate on Successful Phase II Trial of ProtheraCytes© for the Treatment of Acute Myocardial Infarction
MULHOUSE, France, and SUNNYVALE, California USA - July 8, 2024 CellProthera, a private company specializing in cell-based therapies...
11 Jul CellProthera and BioCardia Collaborate on Phase 2 Trial of ProtheraCytes to Treat AMI
July 8, 2024—France-based CellProthera and BioCardia, Inc., which is headquartered in California, announced findings from the collaborative phase 2 trial of CellProthera’s ProtheraCytes for the treatment of acute myocardial infarction (AMI). Additionally, the companies noted they plan to continue the collaboration into phase 3.